Spyre Therapeutics(SYRE)

Focus: Spyre Therapeutics is a public-stage immunology-focused biotechnology company headquartered in Waltham, MA specializing in antibody therapeutics. The company is early-stage with no approved products and modest near-term revenue generation.

Immunology

Profile data last refreshed 8h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

6-1 this month

Stable — net -1 jobs in 30d

3 added, 4 removed. Backfill posture.

Should You Work at Spyre Therapeutics?

AI assessment

High-risk, early-stage opportunity best suited for scientists comfortable with preclinical/clinical-stage volatility and seeking ownership in unproven modalities.

Why Work Here

Aggressive R&D investment ($90M in FY2025) signals commitment to pipeline advancement despite minimal current revenue.
Active hiring in Clinical Development (5 open roles) indicates expansion phase and career progression opportunities in trials management.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

Growing

Jobs increasing

Pipeline & Clinical Trials

SPY001-001

Healthy

PHASE_1

Clinical Trials (1)

NCT06448247A Study of SPY001-001 in Healthy Volunteers

Phase 1

Help build intelligence for Spyre Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Publicly traded status provides equity upside potential and access to capital markets for growth.

Watch Out For

Extreme cash burn ($-338.8M net loss in FY2025) with only $189M cash runway—sustainability is a material concern even with recent funding.
Zero Phase 3 programs and no approved products means 5+ years minimum before commercial validation; significant clinical execution risk.
Minimal headcount and only 7 active job openings suggest limited organizational stability and career ladder depth for most functions.

Generated by Claude from Spyre Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

SPY002-091

Healthy

PHASE_1

Clinical Trials (1)

NCT06672718A Study of SPY002-091 in Healthy Volunteers

Phase 1

SPY003-207

Healthy

PHASE_1

Clinical Trials (1)

NCT06873724A Study of SPY003-207 in Healthy Volunteers

Phase 1

SPY002-072

Healthy

PHASE_1

Clinical Trials (1)

NCT06622070A Study of SPY002-072 in Healthy Volunteers

Phase 1

SPY001

Ulcerative Colitis

PHASE_2

Clinical Trials (2)

NCT07652294Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

Phase 2

NCT07012395A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Phase 2

SPY002-072

Rheumatoid Arthritis

PHASE_2

Clinical Trials (1)

NCT07148414A Study of SPY072 in Rheumatic Disease

Phase 2

SPY072

Hidradenitis Suppurativa (HS)

Phase 2

Clinical Trials (1)

NCT07766005A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

Phase 2

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Top TAs: Immunology, Dermatology

Publications: 2 in PubMed

SEC Filings: 2 available

Open Roles: 6 active jobs

Therapeutic Area Focus

Immunology

3 pipeline

Dermatology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$886K62%

R&D Spend

$90M(10102%)53%

Net Income

-$339M

Hiring Trend

Stable

Open Roles

Added

-2

Filled/Removed

Based on last 4 crawl cycles

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safety.

mAbs

2026

PMID:42106953

Stability of Protein Pharmaceuticals: Recent Advances.

Pharmaceutical research

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Spyre Therapeutics(SYRE)

Should You Work at Spyre Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Spyre Therapeutics(10)

Open Jobs (6)

Senior Director, Intellectual Property Counsel

Director, Regulatory Affairs

Senior Scientist, Translational Science

Director, Drug Safety Physician

Senior Director, Drug Safety and Pharmacovigilance Operations

Associate Director, Clinical Supply Chain

Financials (FY2025)

Hiring Trend

Research Publications(2)